Navigation Links
IFRS Information - First Half of 2007
Date:9/13/2007

6% resulted in a 7% increase in US prescriptions for ADDERALL XR for the six months to June 30, 2007 compared to the same period in 2006.

Sales of ADDERALL XR for the six months to June 30, 2007 were $504.2 million, an increase of 18% compared to the same period in 2006 (2006: $426.8 million). Product sales growth was higher than prescription growth due primarily to a price increase in January 2007.

As previously disclosed, the United States Federal Trade Commission ("FTC") informed Shire on October 3, 2006 that it was reviewing the ADDERALL XR patent litigation settlement agreement between Shire and Barr Laboratories, Inc. ("Barr"). On June 22, 2007, Shire received a civil investigative demand requesting that it provide information to the FTC relating to its settlement with Barr and its earlier settlement with Impax Laboratories, Inc. Shire is cooperating fully with this investigation and believes that the settlements are in compliance with all applicable laws.

VYVANSE

VYVANSE was launched in the US in June 2007. Launch stocks of $55.9 million (before sales deductions) were shipped to wholesalers during June 2007. In accordance with IFRS, sales of these launch stocks have been deferred pending satisfaction of revenue recognition criteria. All launch stocks are expected to be recognized into revenue by the end of 2007.

DAYTRANA

Following its launch in June 2006, DAYTRANA achieved an average market share during the six months to June 30, 2007 of 2%. Net sales for the six months to June 30, 2007 were $31.8 million.

The DAYTRANA and ADDERALL XR market share has helped Shire grow its total share of the US ADHD market to 28% at June 30, 2007 compared to 27% at June 30, 2006 (which included a 1% share relating to ADDERALL which Shire has subsequently divested).

PENTASA

PENTASA's average share of the US oral mesalamine prescription market remained stable at 17% for the six months to June 30, 2007 compared to the same p
'/>"/>

SOURCE Shire plc
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Imaging and Analysis of DIGE Product Information Sheet, Rev B
2. Study affirms information technology-productivity link
3. TrafficCast integrates new information source
4. Rote education fails the Information Age
5. Weather information companies launch data product
6. TeraMedica launches information manager
7. Global information firm reaches diverse markets
8. Preparing for avian flu with information technology
9. Businesses cant hide personal information losses, theft
10. S.C. Johnson lands in No. 2 spot in Information Week 500 list
11. Crate and Barrel deploys Firstlogics Information Quality Suite
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... March 2, 2015  Pfenex Inc. (NYSE MKT: ... development of biosimilar therapeutics, today announced that it ... Healthcare Conference in Miami, FL at the Loews Miami Beach ... officer of Pfenex, will provide an overview of ... 12th at 9:00 am ET. A live audio webcast and ...
(Date:3/2/2015)... 2015 Editor Note: For more ... Moments ago, Analysts Review released new research updates ... (NASDAQ: SSH ), Synergetics USA ... ELOS ), Spectranetics (NASDAQ: SPNC ), and ... single unified platform for investors, to hear about what matters ...
(Date:3/2/2015)... SANTA BARBARA, Calif. , March 2, 2015 ... a biotechnology company developing therapies for autoimmune and ... Trademark Office (USPTO) has issued an important new ... immune system function through the targeting of CLIP. ... the targeted peptide technology underlying VG Life Sciences, ...
(Date:3/2/2015)... Global Stem Cells Group.com ... Shenzhen HANK Bioengineering Co., Ltd. and its Chinese-American ... establish a stem cells training course in the ... 2015. , Shenzhen HANK is a biotechnology company ... microbiologist and virologist, to integrate research, development, production, ...
Breaking Biology Technology:Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 2Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 3Quarterly Report Card of Biotechnology Companies: New Research on Sunshine Heart, Synergetics USA, Syneron Medical, Spectranetics and Thoratec 4VG Life Sciences Granted Key Composition Of Matter Patent 2VG Life Sciences Granted Key Composition Of Matter Patent 3Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 2Global Stem Cells Group Announces Alliance with HANK Bioengineering Co., Ltd. in Shenzhen, China 3
... Launch Interactive, Case-Based Website on Cardiovascular Disease for ... Whether it,s a common heart condition or a ... similar patient. That,s why the Society for Cardiovascular ... Inc. (EVF), an IC Sciences Company, today unveiled ...
... iZumi Bio, Inc., a biotechnology company focused on ... technology with the mission of creating new therapeutics ... cells, today announced the appointments of Berta Strulovici, ... Pathak, Ph.D., as vice president of Business Development. ...
... announced successful,completion of the single-day oral dosing part ... patients with its new anti-cancer drug AXL1717,an,insulin-like growth ... the closely related insulin receptor. The study is ... The results showed that a single-day,dosing of AXL1717 ...
Cached Biology Technology:New Website Connects Physicians to Solve Challenging Cases and Share Experiences 2New Website Connects Physicians to Solve Challenging Cases and Share Experiences 3New Website Connects Physicians to Solve Challenging Cases and Share Experiences 4iZumi Bio Appoints Dr. Berta Strulovici as Chief Technology Officer and Dr. Dushyant Pathak as Vice President of Business Development 2iZumi Bio Appoints Dr. Berta Strulovici as Chief Technology Officer and Dr. Dushyant Pathak as Vice President of Business Development 3Successful Phase I/II Clinical Trial Results From Cancer Patients Treated With Anti-Cancer Drug From Axelar AB 2
(Date:2/24/2015)... Feb. 24, 2015 This report analyzes the worldwide ... separate comprehensive analytics for the US, Canada ... , Asia-Pacific , Middle East ... estimates and forecasts are provided for the period 2013 through ... markets. Market data and analytics are derived from primary and ...
(Date:2/18/2015)... (NASDAQ: CPHD ) today announced that its executives ... to participate via webcast. , Cowen and Company Health ... 3, 2015 at 11.20 a.m. Eastern Time , Raymond ... Wednesday, March 4, 2015 at 10.25 a.m. Eastern Time ... these events, please visit Cepheid,s website at http://ir.cepheid.com ...
(Date:2/10/2015)... 10, 2015  Alere Inc. (NYSE: ALR), a ... results for the quarter ended December 31, 2014. ... President of Alere said, "We made substantial progress ... the global leader in rapid diagnostics and delivering ... Health divestiture in early January enabled us to ...
Breaking Biology News(10 mins):World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11Cepheid to Webcast Upcoming Financial Presentations 2Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25
... MA.April 25th, 2012Aspera, Inc., creators of next-generation software ... speed, and BGI, the world,s largest genomics research ... have partnered to integrate and deploy the Aspera ... technology with "EasyGenomicsTM", BGI,s latest cloud-based Software as ...
... in state in 1970s; Zoo has monitored for beetle since ... Beetle Conservation; the U.S. Fish & Wildlife Service; the Missouri ... to 600 Zoo-bred American burying beetles for the first ... across the 4,040-acre Wah, Kon-Tah Prairie in Southwest Missouri. ...
... reported to increase risk of developing hepatocellular carcinomas (HCC), independent ... of Hepatology , a journal of the American Association ... 70-fold elevated risk of HCC in those with liver cancer ... hepatitis C (HCV). Liver cancer ranks sixth in ...
Cached Biology News:BGI and Aspera collaborate on high-speed data exchange to advance genome research 2First-ever release of endangered burying beetles in Missouri 2First-ever release of endangered burying beetles in Missouri 3First-ever release of endangered burying beetles in Missouri 4Family history of liver cancer increases risk of developing the disease 2
St. Louis encephalitis Immunogen: St. Louis encephalitis. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Mouse Anti-Gemin2...
5-bromo-2'-deoxyuridine (BrdU) Cell Biology Cell Proliferation Bromodeoxyuridine (BrdU) and Related Products...
Rat CINC-2 alpha/beta Affinity Purified Polyclonal Ab...
Biology Products: